JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

Search

Certara Inc

Închisă

SectorSănătate

6.3 5.18

Rezumat

Modificarea prețului

24h

Curent

Minim

6.17

Maxim

6.3

Indicatori cheie

By Trading Economics

Venit

-7.4M

-5.9M

Vânzări

-968K

104M

P/E

Medie Sector

100.714

60.328

Marjă de profit

-5.688

Angajați

1,515

EBITDA

8.6M

32M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+41.67% upside

Dividende

By Dow Jones

Următoarele câștiguri

11 mai 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-49M

985M

Deschiderea anterioară

1.12

Închiderea anterioară

6.3

Sentimentul știrilor

By Acuity

38%

62%

146 / 348 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Certara Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

24 apr. 2026, 19:19 UTC

Achiziții, Fuziuni, Preluări

Intertek Group Rejects EQT's Revised Offer

24 apr. 2026, 23:37 UTC

Achiziții, Fuziuni, Preluări

Scoring the Cook Era -- Barrons.com

24 apr. 2026, 20:51 UTC

Achiziții, Fuziuni, Preluări

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr. 2026, 20:50 UTC

Market Talk
Evenimente importante

Financial Services Roundup: Market Talk

24 apr. 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

24 apr. 2026, 20:39 UTC

Achiziții, Fuziuni, Preluări

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr. 2026, 20:09 UTC

Câștiguri

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24 apr. 2026, 19:48 UTC

Market Talk
Evenimente importante

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24 apr. 2026, 19:25 UTC

Achiziții, Fuziuni, Preluări

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr. 2026, 19:25 UTC

Achiziții, Fuziuni, Preluări

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24 apr. 2026, 19:22 UTC

Câștiguri

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24 apr. 2026, 19:06 UTC

Câștiguri

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24 apr. 2026, 19:05 UTC

Market Talk

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24 apr. 2026, 18:30 UTC

Achiziții, Fuziuni, Preluări

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24 apr. 2026, 18:28 UTC

Achiziții, Fuziuni, Preluări

Intertek Rejects Revised EQT Offer

24 apr. 2026, 18:12 UTC

Market Talk

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24 apr. 2026, 18:06 UTC

Market Talk

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24 apr. 2026, 17:42 UTC

Câștiguri

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24 apr. 2026, 17:28 UTC

Câștiguri

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

24 apr. 2026, 17:28 UTC

Market Talk

Crypto Fear and Greed Index Slides Back to Neutral -- Market Talk

24 apr. 2026, 17:12 UTC

Market Talk

Global Equities Roundup: Market Talk

24 apr. 2026, 17:11 UTC

Market Talk

Apple Seen Gaining Market Share Despite Memory Crunch -- Market Talk

24 apr. 2026, 17:09 UTC

Market Talk
Câștiguri

Intel Seen With Stronger Long-Term Earnings Power -- Market Talk

24 apr. 2026, 17:09 UTC

Achiziții, Fuziuni, Preluări

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 apr. 2026, 17:06 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Correction to Advanced Micro Devices Stock Gets Upgraded to Buy. Why It's the Big Winner of Intel Earnings. -- Barrons.com

24 apr. 2026, 16:51 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Two Big Loan Defaults Add to Pain in Private-Credit Funds -- WSJ

24 apr. 2026, 16:20 UTC

Market Talk
Câștiguri

Tech, Media & Telecom Roundup: Market Talk

24 apr. 2026, 16:20 UTC

Market Talk
Evenimente importante

Financial Services Roundup: Market Talk

24 apr. 2026, 16:20 UTC

Market Talk
Câștiguri

Auto & Transport Roundup: Market Talk

24 apr. 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

Comparație

Modificare preț

Certara Inc Așteptări

Obiectiv de preț

By TipRanks

41.67% sus

Prognoză pe 12 luni

Medie 8.5 USD  41.67%

Maxim 10 USD

Minim 7 USD

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCertara Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

8 ratings

3

Cumpărare

5

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

11.27 / 12.79Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Very Strong Bullish Evidence

Termen lung

Strong Bullish Evidence

Sentiment

By Acuity

146 / 348 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat